Metabolic Tumor Volume Predicts for Recurrence and Death in Head-and-Neck CancerPage 1335
T. H. La, E. J. Filion, B. B. Burnbull, J. N. Chu, P. Lee, K. Nguyen, P. Maxim, A. Quon, E. E. Graves, B. W. Loo, Jr., and Q.-T. Le
In this article, the authors describe the clinical outcomes in patients with locally advanced head-and-neck cancer treated with definitive chemoradiotherapy who underwent 18F-fluorodeoxyglucose–positron emission tomography (FDG-PET) imaging for initial staging and radiation treatment planning. Specifically, this study assessed the prognostic value of the tumor burden, as shown by the metabolic tumor volume measured on FDG-PET images. A high metabolic tumor volume was shown to be a significant independent predictor of poor treatment outcome and could be used for risk stratification in future studies.
Local Control and Survival Following Concomitant Chemoradiotherapy in Inoperable Stage I Non–Small-Cell Lung CancerPage 1371
M.-P. Campeau, A. Herschtal, G. Wheeler, M. Mac Manus, A. Wirth, M. Michael, A. Hogg, E. Drummond, and D. Ball
In this work, the authors explored the role of concomitant chemoradiotherapy (CRT) in patients with inoperable stage I non–small-cell lung cancer (NSCLC). The outcomes of 73 patients with stage I NSCLC treated with radical radiotherapy with or without concomitant chemotherapy were reviewed. Despite the use of CRT and routine staging with F-18 FDG PET, both local and distant recurrences were important causes of treatment failure.
Gleason Pattern 5 Prostate Cancer: Further Stratification of Patients With High-Risk Disease and Implications for Future Randomized TrialsPage 1419
A. Nanda, M-H. Chen, A. A. Renshaw, and A. V. D'Amico
While men with Gleason score 8-10 prostate cancer (PC) are at high risk for PSA recurrence following definitive monotherapy, this study demonstrated that, after adjustments for treatment, age, and known PC prognostic factors, men with a biopsy Gleason score of 8 are at a lower risk of PSA recurrence than are those with any grade 5 disease (i.e., Gleason score 9-10 or 7 with tertiary grade 5). This finding suggests that the pre-randomization stratification of men with high-risk PC based on the presence or absence of any grade 5 component (primary, secondary, or tertiary) should help to better identify in future clinical trials men who would benefit from the addition of systemic therapy to the current standard of care.
Excellent Local Control From Radiation Therapy for High-Risk NeuroblastomaPage 1549
H. G. Gatcombe, R. B. Marcus, H. M. Katzenstein, M. Tighiouart, and N. Esiashvili
Radiation therapy to primary and metastatic sites of disease is an accepted component of combined-modality treatment for high-risk neuroblastoma. However, the radiation dose and indications for the irradiation of metastatic sites are not well-defined. The authors reviewed their institutional experience with the radiation therapy treatment of patients with high-risk neuroblastoma. Excellent local control was achieved in patients given doses of 21-24 Gy, with minimal residual disease present after initial chemotherapy and resection; however, dose escalation may have a role in patients with significant residual disease. Distant failure predominated and occurred at originally involved unirradiated sites, warranting further prospective evaluation of the need for radiation therapy in this setting.
FULL TEXT
Page 1335